Seroquel maker to pay $5.5M in latest settlement related to off-label use of the antipsychotic drug

Share this article:

Drugmaker AstraZeneca recently settled a lawsuit with the state of Kentucky over allegations of improperly marketing its atypical antipsychotic drug Seroquel. Under the settlement, the London-based pharmaceutical company will pay the Bluegrass State $5.5 million.

AstraZeneca improperly marketed the schizophrenia and bipolar disorder drug for off-label uses, including treatment of dementia and Alzheimer's disease, according to the state's attorney general, Jack Conway. As of August 2004, about 15% of Seroquel users in Kentucky were older than 65, but the drug company had not established Seroquel's “safety or effectiveness” for this group, according to the attorney general.

A spokesman for AstraZeneca said the company denies the allegations and settled with Kentucky to avoid a lengthy and expensive legal battle, according to the Bureau of National Affairs.

This is the latest example of AstraZeneca settling a suit related to marketing Seroquel for off-label uses. The company paid out $520 million in a federal settlement in 2010 and $68.5 million in a settlement involving 37 states in 2011.

Seroquel was the antipsychotic drug most often given to nursing home residents as of 2010, according to a recently published study.

Share this article:

More in News

Skilled nursing facilities with poor quality ratings do not readmit more patients to hospitals, researchers find

Skilled nursing facilities with poor quality ratings do ...

Low-quality and high-quality skilled nursing facilities readmit about the same proportion of residents to hospitals, suggest research findings recently published in the American Journal of Medical Quality.

Cipro and related antibiotics increase MRSA risk in long-term care facilities, study ...

Long-term care residents on a fluoroquinolone antibiotic such as Cipro are at an increased risk for methicillin-resistant Staphylococcus aureus, researchers in France have found.

Jonathan Blum, who oversaw long-term care reforms, resigns as head of Medicare

The nation's top Medicare official, Jonathan Blum, is leaving his post next month, news outlets reported Tuesday. Blum became a familiar figure to long-term care providers through Open Door Forum calls and other outreach efforts during his five-year tenure, as he guided implementation of Medicare ...